Suppositories are solid or semi-solid dosage forms, typically designed to melt to release a drug into a body cavity where they will be absorbed through mucosal membranes — particularly for rectal, vaginal, or urethral administration. The suppository market is steadily expanding as acceptance of this dosage form grows. In the U.S. and Canada, it was valued at $738 million in 2023 and is projected to reach $1.3 billion by 2035.
But suppository dosage forms present distinct manufacturing challenges when transitioning from small-scale R&D to commercial production. While most commercial suppositories are designed for immediate release, interest in controlled-release formulations is growing, particularly in women’s health and chronic therapies. These products introduce added formulation and process complexity, making early collaboration between R&D and manufacturing teams even more essential.
Successfully navigating scale-up challenges in suppository drug products demands proactive regulatory planning, robust quality control approaches and cross-functional collaboration during technology transfer.
Unique Suppository Formulation Requirements
Unlike more common oral formulations, suppositories contain little or no water and are usually based on hard fats, polyethylene glycols (PEGs) or cocoa butter. Base selection is critical, as it significantly affects drug release, stability and patient acceptability.
The drug’s solubility in the base impacts its release rate. For instance, some APIs can be extremely hydrophilic or polar, which can complicate things when you want to formulate with an organic compound. In such cases, a suspension product may be necessary to incorporate the API effectively. Therefore, understanding physical properties like solubility is essential to ensure compatibility with the delivery system. Additionally, pH must be carefully adjusted to align with the rectal or vaginal environments.
Suppositories are also more difficult to manufacture than many oral products. They require more specialized equipment to fill molds and maintain the proper semi-solid consistency. They also have more stringent regulatory and quality control requirements.
Scale-Up Challenges
Transitioning from R&D to commercial manufacturing is not straightforward, particularly for suppositories. Scaling up introduces unique challenges due to the melting nature of the base, the presence of thermolabile ingredients, and the critical solidification behavior of the formulation.
To maintain dose uniformity, stability and overall product integrity during the transition from lab to pilot or commercial scale, temperature control, mixing and fill procedures must be precisely optimized. Companies often underestimate the gap between benchtop formulation and large-scale production. In R&D, hand-filling molds and working with small batches is common, with the focus on achieving the correct formulation. At commercial scale, however, accuracy and consistency take precedence, requiring a shift to specialized filling equipment. That makes early collaboration between R&D and commercial teams essential to ensure a smooth tech transfer — especially when accommodating the complex formulation demands typical of suppositories, which can contain 10-15 different ingredients.
If pharma companies are utilizing a contract development and manufacturing organization, flexibility and trust are necessary. Sometimes, pharma developers provide their CDMOs a directive to use a predefined formula. While some formulas work well in a small-scale R&D batch, they may present challenges during scale-up. An experienced CDMO can raise these concerns early in the process, drawing on a deep understanding of the physical properties of formulation components, how these components will interact with one another, and the equipment requirements for scale-up. Experts evaluate not only the ingredients themselves but also the order of addition, as this can significantly impact solubility and overall product performance.
Developers may have compelling reasons for wanting to preserve a formulation — such as the use of a validated analytical method or established manufacturing process. In some cases, even when potential risks are clearly communicated, developers may choose to proceed with the existing approach. As a CDMO, we have encountered situations where this led to technical challenges, such as batch failures resulting from incomplete congealing with solubility or phase separation issues. While setbacks like these are part of the development process, these experiences underscore the importance of open, collaborative dialogue and thorough early-phase technical evaluation. Engaging in proactive risk assessments and formulation feasibility studies can significantly reduce the likelihood of downstream issues, ensuring a more efficient path to product success.
Another significant challenge in commercial manufacturing relates to compatibility between the formulation and the container closure system. Suppositories are commonly packaged in primary films composed of materials such as polyvinyl chloride (PVC) and polyethylene (PE) or laminates. If the formulation interacts adversely with these packaging materials — either through migration, sorption or chemical reactivity — it can result in the formation of degradation products or leachables, which compromise product quality, safety and stability. These impurities may not be immediately detectable during routine QC but can emerge over time, especially under accelerated or long-term storage conditions. Such interactions can lead to API degradation, changes in drug release characteristics, or the presence of toxicological safety concerns due to extractables and leachables.
These issues render the product unsuitable for human use under current ICH, FDA and USP regulatory standards. Therefore, comprehensive container closure compatibility studies are essential. These include extractable and leachable studies, stability testing under ICH recommended conditions, sorption studies, evaluation of barrier properties of packaging film, and toxicological risk assessment for any leachables detected.The selection of the container closure system should be made early in development and materials must be evaluated not only for inertness but also for their mechanical integrity, heat sealability and performance under manufacturing conditions — including fill temperature and cooling rates.
Critical Material Attributes and Critical Process Parameters
Manufacturing suppositories — whether rectal, vaginal or urethral — requires meticulous control of both material properties and process parameters to ensure product quality, performance and regulatory compliance. The selection and control of critical material attributes (CMAs) and critical process parameters (CPPs) are key components of a robust quality by design (QbD) approach.
CMAs are physical and chemical properties of APIs, excipients and packaging materials that can directly influence critical quality attributes (CQAs) of the final suppository product such as uniformity, stability, mechanical strength and drug release. Many of these attributes, such as molecular weight in polymers like hyaluronic acid, are vulnerable to degradation from heat, pH, or enzymatic exposure. Early identification and control of these CMAs are essential for developing stable, effective formulations.
However, material properties alone are not sufficient to ensure product quality at commercial scale. CPPs must also be identified, understood and controlled. CPPs are process inputs that can directly impact CMAs and ultimately CQAs of the final suppository product. For suppositories, temperature control is among the most critical CPP. Precise temperature management is required during melting, mixing, pouring, cooling and packaging to prevent API degradation, migration, phase separation or undesirable textural changes.
The behavior of hydrophilic and hydrophobic bases further complicates scale-up: Hydrophilic bases (e.g., PEG) solidify differently than lipophilic ones (e.g., cocoa butter or semi-synthetic glycerides), requiring tailored cooling profiles and mold handling. Improper cooling rates can lead to crystallization, air pockets or uneven API distribution. Fill volume, mold lubrication and handling times are additional CPPs — all of which significantly influence the final product’s integrity, content uniformity and visual appearance.
Overlooking these parameters during development can result in costly scale-up failures, process validation delays and even the need for reformulations.
Early and ongoing collaboration between R&D and commercial teams is essential to proactively identify and mitigate these risks. In some instances, commercial manufacturing may mean procuring specialized equipment or custom molds, a need that should be anticipated in early development — not a discovery the manufacturer wants to save for the eleventh hour.
QC, Analytical and Regulatory Requirements
QC, analytical testing and regulatory compliance are non-negotiable. Every batch must be tested for microbial contamination, assay and active ingredient content to meet label claims. It is critical to establish analytical methods as early as possible because they allow manufacturers to verify that the final product meets each requirement, especially the required dosage.
Analytical validation becomes particularly important when preparing to scale up. Regulatory expectations can vary significantly depending on the product type. For prescription or 510(k) devices, regulatory involvement is strong from the beginning. The U.S. FDA has strict guidelines and requirements for each:
- A new drug requires extensive characterization, including stability and pharmacokinetics data
- A generic drug must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug (RLD)
- A device will be tested against a predicate device already cleared by FDA
For over-the-counter or cosmetic products, the regulatory requirements are not as stringent but are still mandatory. However, they are too often treated as afterthoughts, leading to late-stage issues. In all instances, regulatory planning and risk assessment benefit from a QbD approach, based on industry guidance documents, and supported by open communication between R&D and manufacturing teams.
Looking Forward: Controlled Release Considerations
Controlled release formulations for suppositories represent a significant area of potential and are gaining interest as a therapeutic option in the treatment of chronic diseases. Controlled release suppositories have the ability to sustain therapeutic drug levels over an extended period of time, offering advantages in terms of dosing frequency, patient compliance and target delivery. Achieving controlled release in suppositories typically requires the use of specific hydrophilic adhesive polymers and hard fat bases, with some research showing that a cocoa butter base may be useful for rapid gelling and adherence to mucous membranes for sustained release and site-specific drug absorption.
Another promising use of controlled release formulations is in women’s health. Vaginal delivery can bypass hepatic first-pass metabolism and enable targeted delivery to the reproductive tract, including the uterus, while reducing systemic exposure compared to oral routes.
Controlled release demands additional formulation and process development effort. It requires careful consideration of the excipient compatibility, API solubility, as well as interactions between a drug, suppository base and any other excipients. One strategy involves modifying the melting points or ratios of lipophilic base components to modulate the drug release rate. Importantly, manufacturing processes would also have to be coordinated precisely to ensure the right drug release profile.
Collaboration is Key
Collaboration between R&D and manufacturing teams is a make-or-break factor for suppository development. Smooth tech transfer requires more than good documentation — they demand close communication across formulation, regulatory, analytical and operations teams. It helps plan for scale-up risks before they escalate at the commercial stage.
In R&D, we study material behavior and develop process parameters and controls in a controlled environment, working with a very scaled-down version of the commercial process. This makes the scale-up phase a critical transition point in commercial manufacturing. Special requirements — such as custom molds, manual processes or equipment limitations — can become roadblocks if not identified early. However, these challenges are often preventable. Clear and consistent communication between R&D and commercial teams ensures that potential issues are anticipated and addressed with the appropriate process controls and equipment needed for the project.
References
U.S. & Canada Pharmaceutical Suppositories Market, by Type. (2024, Nov). Allied Market Research.
Container Closure Systems for Packaging Human Drugs and Biologics. (1999, May). US Food and Drug Administration. [Guidance for Industry]
Ramamoorthy, S. and Hotha, K. (2024, Dec). Strengthening extractable & leachable study submissions: best practices to avoid regulatory deficiencies. Am J Anal Chem. 16(4), 211-223.
Zhu, Y. and Pang, Z. (2019, Jan). Hyaluronic acid in drug delivery applications. Natural Polysaccharides in Drug Delivery and Biomedical Applications. 307–325.
Use of International Standard ISO 10993-1, Biological Evaluation of Medical Devices – Part 1: Evaluation and Testing Within a Risk Management Process. (2023, Sept). U.S. Food and Drug Administration. [Guidance for Industry]
510(k) Clearances. (Updated 2024, May). U.S. Food and Drug Administration. [Accessed June 9, 2025]
Havaldar, V., et. al. (2015, June). Rectal suppository as an effective alternative for oral administration. Res J Pharm Technol. 8(6), 759–766.
Subi, M.T. et. al. (2024, May). Vaginal drug delivery system: A promising route of drug administration for local and systemic diseases. Drug Discov Today. 29(6):104012.